Cue Biopharma, INC DEF 14A proxy statements

Cue Biopharma is holding a special meeting on June 1, 2026, to seek stockholder approval for the issuance of shares upon warrant exercise related to a licensing deal and private placement, and to approve its 2026 Stock Incentive Plan.

Cue Biopharma, Inc. is seeking stockholder approval for a reverse stock split at a ratio between 1-for-30 and 1-for-50 to maintain its Nasdaq listing and enhance investor appeal.

Cue Biopharma, Inc. has issued a supplement to its proxy statement, disagreeing with Institutional Shareholder Services' recommendation against its 2025 Stock Incentive Plan, asserting ISS double-counted shares and inflated plan cost.

Cue Biopharma's upcoming annual meeting on June 4, 2025, will include proposals to increase authorized shares, elect board members, ratify the accounting firm, approve executive compensation, and adopt a new stock incentive plan.

Cue Biopharma is asking stockholders to approve an amendment to increase authorized shares and a new stock incentive plan at its virtual annual meeting on June 4, 2025.

Cue Biopharma is asking stockholders to approve an amendment to their corporate charter to increase the number of authorized shares, providing flexibility for future financing and strategic opportunities.

Cue Biopharma files an amendment to its definitive proxy statement to include the proxy card inadvertently omitted in the original filing.

Cue Biopharma announces its 2024 Annual Meeting of Stockholders to be held virtually on June 5, 2024, featuring proposals for director elections, auditor ratification, and executive compensation.

Cue Biopharma will hold its annual stockholders meeting on June 5, 2024, to elect directors, ratify the appointment of its accounting firm, and conduct an advisory vote on executive compensation.